Advertisement
Document › Details
Fujifilm Irvine Scientific, Inc.. (1/2/19). "Press Release: Accelerating the Growth of the Cell Culture Media Business. Leading Cell Culture Media Company Changes Name to »Fujifilm Irvine Scientific, Inc.«".
Organisation | Irvine Scientific Sales Company Inc. | |
Today | Fujifilm Irvine Scientific Inc. (FISI) | |
Group | Fujifilm (Group) | |
Organisation 2 | Zyme Communications Ltd. | |
Product | cell culture media | |
Product 2 | BIOTECH | |
Index term 2 | Fujifilm–Zyme Communications: public relations, 201901 service existent for Fujifilm Irvine Scientific by Zyme | |
Person | Sukeno, Kenji (Fujifim 201712 President of Fujifilm Corp) | |
FUJIFILM Irvine Scientific, Inc. (President: Yutaka Yamaguchi, FISI), a US subsidiary of FUJIFILM Corporation (President: Kenji Sukeno), and a leading company in cell culture media, today announced that on January 1, 2019 in the United States, the company changed its name from Irvine Scientific Sales Company, Inc.
The new company name combines the “FUJIFILM” brand, which is recognized worldwide as a global company, together with the “Irvine Scientific” brand, which has been established as a leading company for cell culture media. Under this new company name, FISI will further expand its cell culture media business and accelerate the growth of Fujifilm Group’s bio-medical field through synergies and collaborations.
FISI provides a wide range of products including cell culture media for biopharmaceutical production, in vitro fertilization, and cell therapy. The company can develop the optimal custom culture medium to meet the customers’ needs by utilizing its extensive capabilities in quality control, research and development, as well as its proven track record and know-how accumulated over the years.
FISI will accelerate the development of high-performance and highly competitive cell culture media solutions by combining its advanced development and manufacturing capabilities with FUJIFILM Group’s bio-related technologies. Also, it will further expand the media business by leveraging FUJIFILM Group’s collective capabilities in the bio-medical field.
By developing and providing high-performance cell culture media for biopharmaceutical production, in vitro fertilization, and cell therapy, FISI will contribute to advancing biopharmaceutical development, improving the quality of assisted reproductive technologies, and promoting the commercialization of regenerative medicine.
1. New company name: FUJIFILM Irvine Scientific, Inc.
2. Date of change: January 1, 2019 in the United States
[Reference]
Outline of FUJIFILM Irvine Scientific, Inc.
Company Name
FUJIFILM Irvine Scientific, Inc.
Location
Santa Ana, California, U.S.A.
Year of incorporation
1970
CEO
Yutaka Yamaguchi
Shareholder
FUJIFILM Holdings America Corporation (100%)
For inquiries on information in this media release, contact:
Media Contacts:
FUJIFILM Corporation
Corporate Communications Division
TEL: +81-3-6271-2000
FUJIFILM Irvine Scientific, Inc.
Phone: +1 949-261-7800 x145
Email: [email protected]
Lorna Cuddon, Zyme Communications
Phone: +44 (0)7811996942
Email: [email protected]
Record changed: 2023-06-05 |
Advertisement
More documents for Fujifilm (Group)
- [1] Fujifilm Diosynth Biotechnologies UK Ltd.. (8/20/24). "Press Release: Fujifilm Diosynth Biotechnologies Celebrates Opening of Billingham, UK Microbial Manufacturing Facility". Billingham....
- [2] Fujifilm Diosynth Biotechnologies UK Ltd.. (12/2/21). "Press Release: Fujifilm Diosynth Biotechnologies Confirms £400 Million Investment Plans to Create the Largest Multi-modal Biopharmaceutical Manufacturing Site in the United Kingdom". Billingham....
- [3] Rentschler Biopharma SE. (10/28/21). "Press Release: Rentschler Biopharma Appoints Dr. Robert Panting as General Manager of Rentschler ATMP Ltd., Center of Excellence for Cell and Gene Therapy". Laupheim & Stevenage....
- [4] TreeFrog Therapeutics SAS. (2/5/20). "Press Release: TreeFrog Therapeutics Brings in Senior Profiles to Drive the Advent of High-quality and Affordable Allogenic Cell Therapies". Bordeaux....
- [5] Selexis S.A.. (1/9/20). "Press Release: Selexis Promotes Dr. Yemi Onakunle to Chief Business Officer". Geneva....
- [6] Fujifilm Corporation. (11/14/19). "Press Release: Fujifilm Announces Expansion of its Biopharmaceutical Contract Development and Manufacturing Business". Tokyo....
- [7] Genovis AB. (5/16/19). "Press Release: Genovis Signs Distribution Agreement with Fujifilm Wako Pure Chemical for Japan, Taiwan and Singapore Markets"....
- [8] Biogen Inc.. (3/12/19). "Press Release: Biogen Enters Into an Agreement to Sell Its Large-Scale Biologics Manufacturing Site in Hillerød, Denmark to Fujifilm". Cambridge....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top